Frontlight ResearchEarly access
Taking peoplePhase 2
The dual orexin receptor antagonist daridorexant as an adjunct to improve buprenorphine maintenance therapy of opioid use disorder
Key facts
- Who runs it
- Linkopings Universitet
- Where
- Sweden7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 192 people, planned
- Started
- 4 Apr 2025
- Expected to end
- 31 Aug 2029
- Type of study
- Interventional
- Record updated
- 7 September 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Men and women aged 20 - 65 years
- Meet criteria for moderate-to-severe OUD ”opioid dependence” according to ICD-10, confirmed using a checklist of DMS-5 criteria for OUD by a trained nurse or physician. Other, co-morbid substance use disorders will be evaluated by obtaining a history and carrying out a chart review; these will be confirmed using a checklist of DSM-criteria for the respective substance, and will be recorded, but will not influence eligibility except as specified below
- ≥1 year duration of OUD
- Prospective participants will be eligible if they are not in stable remission, or if, despite being in stable remission from opioid use, they continue to use other substances in a manner that indicates they stand to potentially benefit from participating
- Both patients not enrolled in OMT at the time of screening, and those with ongoing OMT with transmucosal buprenorphine formulations at that time will be eligible. Patients not currently enrolled in OMT will first be stabilized on transmucosal buprenorphine according to clinical routine
- Able to speak and read Swedish
- Willing to provide informed consent
Who cannot take part
- Patients with concomitant use of strong CYP3A4 inhibitors (see Appendix 1 of protocol)
- Patients with any serious psychiatric condition unless stable under treatment
- Patients with any other condition or circumstances that, in the assessment of the investigator, lead to participation in the study not being in the best interest of the patient
- Patients with severe respiratory insufficiency
- Patients with any other serious medical condition, unless stable under treatment
- Patients already in OMT with a depot formulation of buprenorphine, or who have been in OMT with a depot formulation of buprenorphine within the past 12 months
- Patients enrolled in OMT with methadone
- Patients with a diagnosis of narcolepsy
- Women who are pregnant or plan on becoming pregnant, or who are nursing
- Women of child-bearing potential will have to agree to practice reliable contraception (see Appendix 2 of protocol), or document that they intend to abstain from sexual intercourse
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial is currently available in Sweden.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate whether daridorexant can reduce illicit substance use compared compared to placebo, when provided as an adjuntive treatment to OUD patients maintained on depot buprenorphine.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from 2024-517482-16-00, who can take part
- Record updated
- 7 September 2026